Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1985 Jul;52(1):1–6. doi: 10.1038/bjc.1985.140

The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis.

J Cuzick, E H Cooper, I C MacLennan
PMCID: PMC1977159  PMID: 3893505

Abstract

The levels of serum beta 2 microglobulin, blood urea concentration, serum creatinine, haemoglobin and performance status have been measured in 476 patients in the Medical Research Council's 4th trial for myelomatosis. Levels of serum beta 2 microglobulin were also subsequently measured in 208 patients who achieved a stable "plateau" condition. Serum beta 2 microglobulin levels, uncorrected for serum creatinine, were found to be the single most powerful prognostic variable available at presentation. Multivariate analysis showed that only the addition of haemoglobin levels could improve upon this and the improvement, though statistically significant (P = 0.006), appeared to be of much less clinical value. The prognostic value of serum beta 2 microglobulin at plateau appeared to be equally large for a given difference in value, but the variability between patients was much less at that time. Serum beta 2 microglobulin would appear to be a key measurement for assessing the prognosis and response to treatment in patients with myelomatosis.

Full text

PDF
1

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bataille R., Durie B. G., Grenier J. Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br J Haematol. 1983 Nov;55(3):439–447. doi: 10.1111/j.1365-2141.1983.tb02158.x. [DOI] [PubMed] [Google Scholar]
  2. Bataille R., Grenier J., Sany J. Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment--a prospective study of 160 patients. Blood. 1984 Feb;63(2):468–476. [PubMed] [Google Scholar]
  3. Bataille R., Magub M., Grenier J., Donnadio D., Sany J. Serum beta-2-microglobulin in multiple myeloma: relation to presenting features and clinical status. Eur J Cancer Clin Oncol. 1982 Jan;18(1):59–66. doi: 10.1016/0277-5379(82)90025-6. [DOI] [PubMed] [Google Scholar]
  4. Buckman R., Cuzick J., Galton D. A. Long-term survival in myelomatosis. A report to the MRC working party on leukaemia in adults. Br J Haematol. 1982 Dec;52(4):589–599. doi: 10.1111/j.1365-2141.1982.tb03935.x. [DOI] [PubMed] [Google Scholar]
  5. Cassuto J. P., Krebs B. P., Viot G., Dujardin P., Masseyeff R. beta 2 Microglobulin, a tumour marker of lymphoproliferative disorders. Lancet. 1978 Jul 8;2(8080):108–109. doi: 10.1016/s0140-6736(78)91428-9. [DOI] [PubMed] [Google Scholar]
  6. Child J. A., Crawford S. M., Norfolk D. R., O'Quigley J., Scarffe J. H., Struthers L. P. Evaluation of serum beta 2-microglobulin as a prognostic indicator in myelomatosis. Br J Cancer. 1983 Jan;47(1):111–114. doi: 10.1038/bjc.1983.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cresswell P., Springer T., Strominger J. L., Turner M. J., Grey H. M., Kubo R. T. Immunological identity of the small subunit of HL-A antigens and beta2-microglobulin and its turnover on the cell membrane. Proc Natl Acad Sci U S A. 1974 May;71(5):2123–2127. doi: 10.1073/pnas.71.5.2123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Durie B. G., Salmon S. E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975 Sep;36(3):842–854. doi: 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  9. Evrin P. E., Wibell L. Serum 2 -microglobulin in various disorders. Clin Chim Acta. 1973 Jan 24;43(2):183–186. doi: 10.1016/0009-8981(73)90449-x. [DOI] [PubMed] [Google Scholar]
  10. Garewal H., Durie B. G., Kyle R. A., Finley P., Bower B., Serokman R. Serum beta 2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders. J Clin Oncol. 1984 Jan;2(1):51–57. doi: 10.1200/JCO.1984.2.1.51. [DOI] [PubMed] [Google Scholar]
  11. Kin K., Sakurabayashi I., Kawai T. Beta2-microglobulin levels of serum and ascites in malignant diseases. Gan. 1977 Aug;68(4):427–434. [PubMed] [Google Scholar]
  12. Messner R. P. Beta 2-microglobulin: an old molecule assumes a new look. J Lab Clin Med. 1984 Aug;104(2):141–145. [PubMed] [Google Scholar]
  13. Norfolk D., Child J. A., Cooper E. H., Kerruish S., Ward A. M. Serum beta 2-microglobulin in myelomatosis: potential value in stratification and monitoring. Br J Cancer. 1980 Oct;42(4):510–515. doi: 10.1038/bjc.1980.273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Revillard J. P., Vincent C. La beta2-microglobuline en pathologie. Pathol Biol (Paris) 1978 Sep;26(6):279–281. [PubMed] [Google Scholar]
  15. Scarffe J. H., Anderson H., Palmer M. K., Crowther D. Prognostic significance of pretreatment serum beta 2-microglobulin levels in multiple myeloma. Eur J Cancer Clin Oncol. 1983 Oct;19(10):1361–1364. doi: 10.1016/0277-5379(93)90004-o. [DOI] [PubMed] [Google Scholar]
  16. Shuster J., Gold P., Poulik M. D. beta 2-microglogulin levels in cancerous and other disease states. Clin Chim Acta. 1976 Mar 15;67(3):307–313. doi: 10.1016/0009-8981(76)90339-9. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES